Bristol-Myers Squibb Company BMY SPXR3KPHARMA

Q: What is the current share price of Bristol-Myers Squibb Company (BMY)?

As of 2026-09-07 16:24 PDT, Bristol-Myers Squibb Company (BMY) trades at $66.82 on NYSE. Its 52-week range is $41.21 to $68.09.

Q: What is the market capitalisation of BMY?

Bristol-Myers Squibb Company (BMY) has a market capitalisation of $136.49B on NYSE.

Q: What is the P/E ratio of BMY?

BMY trades at a trailing price-to-earnings (P/E) ratio of 14.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.92.

Q: Does BMY pay a dividend?

Bristol-Myers Squibb Company (BMY) currently offers a dividend yield of 3.93%.

Q: What is the return on equity (ROE) of BMY?

BMY has a return on equity (ROE) of 46.60%.

Q: Is BMY a good stock to buy?

This page provides a data-driven analysis of Bristol-Myers Squibb Company (BMY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - General · United States

https://www.bms.com

Company Profile ↓

$66.82

+46.35% 1Y

Mkt Cap$136.49B

P/E14.72

P/B5.92

Div. Yield3.93%

52W High$68.09

52W Low$41.21

Book Value$10.93

EPS (TTM)$4.54

Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 46.6%, reflecting efficient use of shareholder capital.

Reasonable Valuation

Trades at a P/E of 14.7, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 18.9%.

Dividend Income

Offers a dividend yield of 3.93%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $48.19B (-0.2% YoY); net profit $7.05B.
Trailing 12 Months Year-on-year growth — revenue +5.7%, earnings +153.1%.
5-Year Trend Long-term compounding — revenue CAGR 6.5%, profit CAGR 6.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	6.46%
1 Year:	5.70%

Compounded Profit Growth

5 Years:	6.78%
1 Year:	153.10%

Stock Price Performance

1 Year:	+46.35%
6 Months:	+13.24%
3 Months:	+17.99%
1 Month:	+4.16%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 95% of range

$41.21 $68.09

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)56.57 · Neutral

Price Performance

1M+4.16%

3M+17.99%

6M+13.24%

1Y+46.35%

Valuation vs Sector

P/E of 14.72 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 46.6%.
Attractive dividend yield of 3.93%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

14.72

Industry PE

25.17

Forward P/E

10.20

PEG Ratio

2.44

Book Value

$10.93

Price to Book

5.92

P/S

2.69

EV/EBITDA

8.72

Dividend Yield

3.93%

Growth (CAGR)

Revenue 5Y

6.46%

Profit 5Y

6.78%

Revenue (YoY)

5.70%

Earnings (YoY)

153.10%

Profitability & Returns

ROCE

ROE

46.60%

ROA

10.72%

Profit Margin

18.87%

Op Margin

34.42%

Gross Margin

71.66%

EPS (Latest Qtr)

$1.62

EPS (TTM)

$4.54

Balance Sheet & Liquidity

Debt/Equity

2.02

Quick Ratio

1.29

Current Ratio

1.53

Debt

$45.05B

Total Assets

$87.63B

Current Assets

Working Capital

Ownership

Promoter Holding

0.10%

Chg in Prom Hold

-0.00%

FII / Inst Holding

84.70%

Chg in FII Hold

0.02%

Financial Snapshot

Enterprise Value

$136.49B

Total Revenue (TTM)

$49.19B

EBITDA

$18.93B

Free Cash Flow

$8.11B

Operating Cash Flow

$12.78B

Shares Outstanding

2.04B

Gross Margin

71.66%

Payout Ratio

55.29%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BMY Bristol-Myers Squibb Company SPXR3KPHARMA	66.82	14.72	$136.49B	3.93%	-	46.60%	6.46%	6.78%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	4.93B	5.14B	5.25B	5.45B	5.19B	5.70B	5.69B	5.97B	5.92B	6.27B	6.01B	7.95B	10.78B	10.13B	10.54B	11.07B	11.07B	11.70B	11.62B	11.65B	11.89B	11.22B	11.34B	11.23B	10.97B	11.87B	12.20B	11.89B	11.20B	12.27B	12.22B	11.49B	12.97B
Gross Profit	3.15B	2.97B	3.33B	3.34B	3.67B	3.62B	3.86B	3.66B	3.58B	3.67B	3.77B	3.63B	4.10B	4.06B	4.30B	4.10B	4.30B	4.22B	5.45B	7.12B	7.43B	8.04B	8.16B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-130.00M	706.00M	-197.00M	1.20B	1.17B	1.20B	894.00M	1.57B	916.00M	845.00M	-2.33B	1.49B	373.00M	1.90B	1.16B	1.71B	1.43B	1.35B	-1.06B	-775.00M	-85.00M	1.87B	-10.03B	2.02B	1.05B	1.55B	1.28B	1.42B	1.61B	2.26B	2.07B	1.93B	-11.91B	1.68B	1.21B	2.46B	1.31B	2.20B	2.68B	3.32B
Diluted EPS	-0.08	0.42	-0.12	0.71	0.69	0.72	0.53	0.94	0.56	0.51	-1.42	0.91	0.23	1.16	0.71	1.04	0.87	0.83	-0.55	-0.34	-0.04	0.82	-4.45	0.89	0.47	0.69	0.59	0.66	0.75	1.07	0.99	0.93	-5.89	0.83	0.60	1.20	0.64	1.08	1.31	1.62
R&D Expense	1.86B	1.13B	-	1.14B	1.27B	1.14B	-	1.30B	1.68B	1.56B	-	1.25B	2.44B	1.28B	-	1.35B	1.32B	1.38B	-	2.37B	2.52B	2.50B	-	2.22B	2.48B	2.98B	2.26B	2.32B	2.42B	2.32B	2.26B	2.24B	2.69B	2.90B	2.37B	2.26B	2.58B	2.53B	2.65B	2.96B

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	15.62B	17.71B	18.81B	19.48B	21.24B	17.62B	16.39B	15.88B	16.56B	19.43B	20.78B	22.56B	26.14B	42.52B	46.38B	46.16B	45.01B	48.30B	48.19B
Gross Profit	-	-	13.67B	14.21B	15.65B	13.01B	11.77B	11.95B	12.65B	14.48B	14.68B	16.09B	18.07B	30.75B	-	-	-	-	-
Net Income	2.17B	5.25B	10.61B	3.10B	3.71B	1.96B	2.56B	2.00B	1.56B	4.46B	1.01B	4.92B	3.44B	-9.02B	6.99B	6.33B	8.03B	-8.95B	7.05B
Diluted EPS	1.09	2.62	5.34	1.79	2.16	1.16	1.54	1.20	0.93	2.65	0.61	3.01	2.01	-3.99	3.12	2.95	3.86	-4.41	3.46
R&D Expense	3.16B	3.51B	3.65B	3.57B	3.84B	3.90B	3.73B	4.53B	5.92B	5.01B	6.47B	6.33B	6.15B	10.05B	10.20B	9.51B	9.30B	11.16B	9.95B

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 2012	Sep 2012	Dec 2012	Mar 2013	Jun 2013	Sep 2013	Dec 2013	Mar 2014	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	31.67B	36.04B	35.90B	35.96B	36.25B	36.80B	38.59B	33.42B	33.50B	33.45B	33.75B	33.58B	31.95B	31.78B	31.75B	31.89B	32.83B	33.73B	33.71B	32.94B	33.41B	33.98B	33.55B	33.08B	32.64B	33.73B	34.99B	34.83B	55.16B	57.43B	129.94B	129.28B	128.08B	125.54B	118.48B	109.31B	96.82B	95.16B	92.60B	90.04B
Total Equity	15.81B	13.90B	13.62B	13.70B	14.37B	14.71B	15.15B	15.53B	15.38B	15.20B	14.85B	15.69B	15.29B	15.27B	14.27B	14.55B	15.08B	15.78B	16.18B	14.54B	14.82B	14.91B	11.74B	12.91B	12.42B	13.75B	14.03B	15.32B	16.15B	17.75B	51.60B	49.98B	49.16B	50.23B	37.82B	35.95B	31.06B	29.43B	16.34B	18.47B
Cash & Equivalents	2.80B	1.50B	1.66B	1.35B	1.82B	1.77B	3.59B	5.22B	4.28B	4.85B	5.57B	6.29B	4.20B	3.98B	2.38B	2.64B	2.93B	3.43B	4.24B	3.91B	3.47B	4.64B	5.42B	5.34B	5.00B	5.41B	6.91B	7.33B	28.40B	30.49B	12.35B	15.82B	19.93B	19.43B	14.55B	13.98B	9.12B	11.46B	10.35B	10.21B
Long Term Debt	5.21B	7.23B	6.57B	7.18B	7.12B	6.56B	7.98B	7.37B	7.37B	7.27B	7.24B	7.13B	6.62B	6.63B	6.55B	-	-	-	5.72B	7.24B	6.91B	6.98B	6.97B	5.78B	5.67B	5.69B	5.65B	5.63B	24.43B	24.39B	43.39B	46.10B	46.11B	44.61B	48.34B	39.60B	35.06B	36.65B	47.60B	42.85B
Total Liabilities	-	-	22.26B	-	-	-	23.36B	-	-	-	18.77B	-	-	-	17.32B	-	-	-	17.36B	-	-	-	21.70B	-	-	-	20.86B	-	-	-	78.25B	-	-	-	80.60B	73.31B	65.70B	65.67B	76.22B	71.53B
Current Liabilities	-	-	8.28B	-	-	-	12.44B	-	-	-	8.46B	-	-	-	8.02B	-	-	-	8.84B	-	-	-	9.56B	-	-	-	10.65B	-	-	-	18.30B	-	-	-	19.08B	21.87B	21.89B	22.26B	23.77B	23.42B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	3.15B	3.71B	4.07B	4.49B	4.84B	6.94B	3.54B	3.15B	2.10B	3.06B	5.28B	7.07B	8.21B	14.05B	-	13.07B	13.86B	15.19B	14.16B
Investing Cash Flow	-202.00M	5.08B	-4.38B	-3.81B	-1.44B	-6.73B	-572.00M	1.22B	-1.57B	1.48B	-66.00M	-2.00B	-9.91B	-10.86B	-	-1.06B	-2.29B	-21.35B	-4.13B
Financing Cash Flow	-3.21B	-2.58B	-17.00M	-3.34B	-2.66B	-4.33B	-1.07B	-2.44B	-3.62B	-2.65B	-4.08B	-3.54B	7.62B	-1.15B	-	-16.96B	-9.42B	5.13B	-10.35B
Capital Expenditure	-843.00M	-941.00M	-730.00M	-424.00M	-367.00M	-548.00M	-537.00M	-526.00M	-820.00M	-1.22B	-1.05B	-951.00M	-836.00M	-753.00M	-	-1.12B	-1.21B	-1.25B	-1.31B
Free Cash Flow	2.31B	2.77B	3.33B	4.07B	4.47B	6.39B	3.01B	2.62B	1.28B	1.84B	4.22B	6.12B	7.37B	13.30B	-	11.95B	12.65B	13.94B	12.85B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.96B	2.15B	-1.03B	-324.00M
Share Buybacks	-	-	-	576.00M	1.22B	2.40B	433.00M	-	-	231.00M	2.47B	320.00M	7.30B	1.55B	6.29B	8.00B	5.16B	0	0
Dividends Paid	2.21B	2.46B	2.48B	2.20B	2.25B	2.29B	2.31B	2.40B	2.48B	2.55B	2.58B	2.61B	2.68B	4.08B	4.40B	4.63B	4.74B	4.86B	5.04B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	72.7%	72.9%	73.6%	73.8%	71.8%	75.2%	76.4%	74.5%	70.7%	71.3%	69.1%	72.3%	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin %	13.9%	29.6%	56.4%	15.9%	17.5%	11.1%	15.6%	12.6%	9.5%	22.9%	4.8%	21.8%	13.2%	-21.2%	15.1%	13.7%	17.8%	-18.5%	14.6%
ROE %	-	-	-	-	-	14.4%	16.9%	13.5%	11.0%	27.6%	8.6%	35.1%	6.7%	-23.8%	19.5%	20.4%	27.3%	-54.8%	38.2%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Shareholding Pattern

Insiders

0.10%

Institutions

84.70%

Public Float

84.78%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.83%	180.38M	$12.01B
2	Vanguard Capital Management LLC	6.53%	133.34M	$8.88B
3	State Street Corporation	5.01%	102.41M	$6.82B
4	JPMORGAN CHASE & CO	3.51%	71.71M	$4.77B
5	Charles Schwab Investment Management, Inc.	3.31%	67.60M	$4.50B
6	Geode Capital Management, LLC	2.76%	56.44M	$3.76B
7	Vanguard Portfolio Management LLC	2.29%	46.87M	$3.12B
8	NORGES BANK	1.80%	36.87M	$2.45B
9	Bank of America Corporation	1.67%	34.05M	$2.27B
10	Price (T.Rowe) Associates Inc	1.55%	31.71M	$2.11B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BMY

Google News Fri, 14 Aug 2026

Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval Lands - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxORnNmb1o2T2NGZlptV05Oek10STBUY2djeFQ2MWRPbXpmYnZsLTNCcW9faE00UFZ5ZnIxbnhndVRQa0Z3c0ZYRnZqRC00bGNQcVBPZmtOMERucjZyXzlPeE00ZU1XVFU4RUZNTUJZZ0ZaUEVDTVdkQnlZWFk3X3EzWi1pRXFZWHBCWXFpWm…

Google News Mon, 07 Sep 2026

VIRGINIA RETIREMENT SYSTEMS ET Al Takes $99.23 Million Position in Bristol Myers Squibb Company $BMY - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOcm15dlRiOThTWC1vSGVWcVVUWXpjQXJyQ3JValdCRU1CYnRSWkdNTmhYZy1ITDdWV0J2UVNQekdCaDV5M2NXVGhXMzJjcERQQnRWYUtVMlN1b21ENTR3N0pOWndMb0J1d3UxaVFxdlYzUVR1WE1rWHFXajh5QkJYUHBIMEtSdXV5UUNBZH…

Google News hu, 03 Sep 2026

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - Barchart.com

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNeFducGp3bzFza2RGVjVMSnc4dmM1dWNlUXhFYmhnaDNIejJQbEh2MDlFVURoQlNFelJha1pqNndPLXcwS0IyVVBJNGlQMFdaQXZlWl9HMFdqMVFJU2ROLVBKQloyMDEwM1VBNHJINV92NVV0eHZYd0FpdFdySEo1cUFWd05TOTc3UTdwUF…

Google News Sat, 05 Sep 2026

Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup - ChartMill

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWklZTkxDQXRrNllBS3owUnlCVmlET2Q5QnBHMDgzclVlekNUVVdjaFFQZmNXZUo4VE9rVW1JX0F0U2l1dGcybDZDbW16U2xSalJ4RWJ1SmZlelJjTXRCY3RrZVNpUUNZWGRmbUdzMHotTHpOdlNUTEh2NjZHX0tkSE9rdjNORnJhMGF6UE…

Google News Fri, 04 Sep 2026

Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPbDBHLVhyaDJ4Ny0yenc3OV9oN1lqZ2daclpaRE1VRmRHRzhEdjhaSmlsdTBCNVU5dHMxVk1yeE1xSGMzaEJSQnJoeVV3ZHRRX3JUdVFvRmVGR3pGbUJ2YzBiWk9Zb0F6andyTXkwSGVJSGozbnM1VXBWSUpocUthUzNSYV93UVNmX2xpNz…

Google News ue, 18 Aug 2026

Bristol Myers Squibb (BMY) Stock May Be 46% Below Fair Value As FDA Approval Lands - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNaUh1Qk9Xd2Y2di1ta0NMUXpUN29kMjVQRGxTWDFaRVgwR2JnTlJmRzhGOWt0MmxBZ1M3OUR3emZfTHIwQ05LNHhncHlQZUUwblYyaUhfMlZZZmlVVlU2ZmU0aC01dW81dFl1MS0wRlJTU3NEbXhHUGRJYTVEb2hnWlI5c1VQWmpvSTAybT…

BMY — Frequently Asked Questions

What is the current share price of Bristol-Myers Squibb Company (BMY)?

As of 2026-09-07 16:24 PDT, Bristol-Myers Squibb Company (BMY) trades at $66.82 on NYSE. Its 52-week range is $41.21 to $68.09.

What is the market capitalisation of BMY?

Bristol-Myers Squibb Company (BMY) has a market capitalisation of $136.49B on NYSE.

What is the P/E ratio of BMY?

BMY trades at a trailing price-to-earnings (P/E) ratio of 14.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.92.

Does BMY pay a dividend?

Bristol-Myers Squibb Company (BMY) currently offers a dividend yield of 3.93%.

What is the return on equity (ROE) of BMY?

BMY has a return on equity (ROE) of 46.60%.

Is BMY a good stock to buy?

This page provides a data-driven analysis of Bristol-Myers Squibb Company (BMY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Bristol-Myers Squibb Company BMY SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval Lands - Yahoo Finance

VIRGINIA RETIREMENT SYSTEMS ET Al Takes $99.23 Million Position in Bristol Myers Squibb Company $BMY - marketbeat.com

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - Barchart.com

Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup - ChartMill

Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY) - Seeking Alpha

Bristol Myers Squibb (BMY) Stock May Be 46% Below Fair Value As FDA Approval Lands - simplywall.st

BMY — Frequently Asked Questions

What is the current share price of Bristol-Myers Squibb Company (BMY)?

What is the market capitalisation of BMY?

What is the P/E ratio of BMY?

Does BMY pay a dividend?

What is the return on equity (ROE) of BMY?

Is BMY a good stock to buy?

Explore More